Targeting Sirtuins in Thyroid Cancer: Mechanisms, Drug Development, and Emerging Roles in Tumor Immunity and Ferroptosis
Cancers · 27.06.2026 · 18 (13) · 2093
DOI: 10.3390/cancers18132093 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 27.06.2026. Verfasst von Ki Ju Cho und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology, Myongji Hospital, Hanyang University Medical Center, 55 Hwasu-ro 14 beon-gil, Goyang 10475, Republic of Korea. Die Arbeit nennt 188 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Gyeongsang National University Hospital.
Abstract (Originalsprache)
Thyroid cancer (TC) is the most common endocrine malignancy, with incidence increasing worldwide. Although most differentiated TCs have a favorable prognosis, radioiodine (RAI)-refractory differentiated thyroid cancer (DTC), BRAF inhibitor-resistant papillary thyroid cancer, and anaplastic thyroid cancer (ATC) remain major areas of unmet clinical need. The sirtuin (SIRT) family of NAD+-dependent enzymes has emerged as a multifaceted regulator of TC biology, with isoform-specific dichotomous roles: SIRT1, SIRT6, and SIRT7 act as tumor promoters through engagement of BRAF/MAPK, PI3K/AKT, epithelial–mesenchymal transition (EMT), and Hippo pathways, while SIRT3 and SIRT4 function as tumor suppressors via mitochondrial metabolic regulation. This review synthesizes recent developments that expand the therapeutic landscape: (i) the recognition that SIRT7 functions as a desuccinylase with preclinically identified oncogenic substrates, modifying KIF23 in ATC and LATS1 in PTC; (ii) the emerging roles of isoform-specific SIRT axes, including the NAMPT–SIRT1–PD-L1 axis, SIRT6-associated regulatory T-cell biology, and SIRT2 as a T-cell metabolic checkpoint, as determinants of immune microenvironment state and potential modulators of immune checkpoint inhibitor response; and (iii) the SIRT6–nuclear receptor coactivator 4 (NCOA4) ferritinophagy axis as a supported ferroptosis vulnerability in ATC, with potential but still hypothesis-generating relevance to dedifferentiated and RAI-refractory DTC. Importantly, the therapeutic logic for SIRT6 is disease-state-specific rather than contradictory: SIRT6 inhibition is rationalized in BRAF-driven aggressive PTC and DTC contexts where SIRT6 supports MAPK signaling, EMT, and ferroptosis resistance, whereas in SIRT6-high ATC, the same enzyme’s NCOA4-dependent ferritinophagy activity may instead be exploited to enhance ferroptosis sensitivity. We review the current SIRT modulator pharmacological toolkit—including EX-527, OSS_128167, and emerging SIRT7-selective inhibitors—and identify the substantial clinical translation gap, with no SIRT-targeted clinical trial yet conducted in TC, despite strong preclinical rationale. We outline biomarker-stratified combination strategies with BRAF/MEK inhibitors, multikinase inhibitors, immune checkpoint inhibitors, and ferroptosis inducers, prioritizing biomarker-driven preclinical validation and, where supported by efficacy and safety data, subsequent early-phase evaluation in BRAF V600E-mutant and SIRT6-high thyroid cancer. Sirtuins thus represent a mechanistically promising and potentially biomarker-stratifiable therapeutic hypothesis for difficult-to-treat thyroid cancer; however, clinical translation remains at an early stage and requires validated biomarkers, isoform-selective compounds, and disease-specific in vivo evidence.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Otorhinolaryngology, Myongji Hospital, Hanyang University Medical Center, 55 Hwasu-ro 14 beon-gil, Goyang 10475, Republic of Korea.
- Department of Otorhinolaryngology-Head and Neck Surgery, Gyeongsang National University College of Medicine, 79 Gangnam-ro, Jinju 52725, Republic of Korea.
- Institute of Medical Science, Gyeongsang National University College of Medicine, 816-15 Jinju-daero, Jinju 52727, Republic of Korea.
- Department of Pediatrics, Gyeongsang National University College of Medicine, 816-15 Jinju-daero, Jinju 52725, Republic of Korea.
- Department of Surgery, Gyeongsang National University College of Medicine, 816-15 Jinju-daero, Jinju 52725, Republic of Korea.
- Biomedical Research Institute, Gyeongsang National University Hospital, 79 Gangnam-ro, Jinju 52727, Republic of Korea.
ORCID-Profile: Ki Ju Cho, Hayeong Kwon, Seung-Jun Lee, Young-Sool Hah, Jung Je Park
Förderung
- National Research Foundation of Korea
- Gyeongsang National University Hospital
Zitieren
APA
Cho, K. J., Seo, J. H., Kwon, H., Lee, S. J., Hah, Y. S., & Park, J. J. (2026). Targeting Sirtuins in Thyroid Cancer: Mechanisms, Drug Development, and Emerging Roles in Tumor Immunity and Ferroptosis. Cancers, 18(13), 2093. https://doi.org/10.3390/cancers18132093
Vancouver
Cho KJ, Seo JH, Kwon H, Lee SJ, Hah YS, Park JJ. Targeting Sirtuins in Thyroid Cancer: Mechanisms, Drug Development, and Emerging Roles in Tumor Immunity and Ferroptosis. Cancers. 2026;18(13):2093. doi:10.3390/cancers18132093
BibTeX
@article{Cho2026,
author = {Cho, Ki Ju and Seo, Ji Hyun and Kwon, Hayeong and Lee, Seung-Jun and Hah, Young-Sool and Park, Jung Je},
title = {Targeting Sirtuins in Thyroid Cancer: Mechanisms, Drug Development, and Emerging Roles in Tumor Immunity and Ferroptosis},
journal = {Cancers},
year = {2026},
volume = {18},
number = {13},
pages = {2093},
doi = {10.3390/cancers18132093}
}
EUVIMED